Edition:
United States

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Capital Market

0.37USD
2:47pm EST
Change (% chg)

$0.00 (+0.05%)
Prev Close
$0.37
Open
$0.38
Day's High
$0.38
Day's Low
$0.34
Volume
17,076
Avg. Vol
70,572
52-wk High
$2.16
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Pulmatrix Inc - QTRLY Loss Per Share $0.13
Friday, 3 Aug 2018 09:00am EDT 

Pulmatrix Inc ::PULMATRIX REPORTS Q2 2018 RESULTS.PULMATRIX INC - QTRLY LOSS PER SHARE $0.13.PULMATRIX INC - AS OF JUNE 30, 2018, PULMATRIX HAD $8.3 MILLION IN CASH AND CASH EQUIVALENTS.PULMATRIX INC QTRLY LOSS PER SHARE $0.13.  Full Article

Pulmatrix Announces Positive Top-Line Preliminary Results From Part 3 Of The 3-Part Phase 1/1B Clinical Trial Of Pulmazole
Tuesday, 17 Jul 2018 09:00am EDT 

July 17 (Reuters) - Pulmatrix Inc ::PULMATRIX ANNOUNCES POSITIVE TOP-LINE PRELIMINARY RESULTS FROM PART 3 OF THE 3-PART PHASE 1/1B CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE.ALL OBJECTIVES FROM PART 3 SUCCESSFULLY MET.WITH PHASE 1/1B RESULTS FROM PART 3 NOW ALSO IN HAND, PULMATRIX PLANS TO INITIATE A PHASE 2 TRIAL IN ABPA PATIENTS IN Q4 2018.PULMAZOLE WAS SAFE AND WELL TOLERATED ADMINISTERED AS A SINGLE-DOSE OF 20 MG INHALED ITRACONAZOLE IN ASTHMATIC SUBJECTS.  Full Article

Pulmatrix posts Q3 net loss of $0.22 per share
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly ‍net loss per share attributable to common stockholders $0.22​.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article